#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16804	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2680	773.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1901	1901	T	1185	T,G,C,A	1177,3,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16804	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2680	773.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1635	1635	C	1089	C,T,G	1087,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16804	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2680	773.8	0	HET	.	.	.	A69G,C	.	69	69	A	520	520	A	1022	A,G,C	531,487,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28610	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	863.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1940	1940	A	1134	A,G	1132,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28610	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	863.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2574	2574	C	1001	C	1001	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28610	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	863.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2648	2648	A	930	A,G	927,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28610	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	863.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3200	3200	C	1000	C,A,G	997,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2368	folP	852	852	99.88	folP.l15.c4.ctg.1	2087	141.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1106	1108	AAA	243;245;246	A,C,G;A;A	239,3,1;245;246	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2368	folP	852	852	99.88	folP.l15.c4.ctg.1	2087	141.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1337	1339	AGC	239;237;236	A,C;G;C,A	238,1;237;235,1	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3957	190.1	1	SNP	p	S91F	0	.	.	271	273	TCC	870	872	TCC	223;222;222	T;C;C	223;222;222	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3957	190.1	1	SNP	p	D95N	0	.	.	283	285	GAC	882	884	GAC	227;230;230	G;A;C	227;230;230	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3957	190.1	1	SNP	p	D95G	0	.	.	283	285	GAC	882	884	GAC	227;230;230	G;A;C	227;230;230	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	2418	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1849	163.2	1	SNP	p	G45D	0	.	.	133	135	GGC	763	765	GGC	292;297;295	G,C;G;C	291,1;297;295	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1286	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1573	101.8	0	.	n	.	0	A197.	DEL	197	197	A	869	869	A	243	A	243	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5674	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3424	206.6	1	SNP	p	D86N	0	.	.	256	258	GAC	816	818	GAC	258;258;261	G;A,T;C	258;257,1;261	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5674	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3424	206.6	1	SNP	p	S87W	0	.	.	259	261	AGT	819	821	AGT	267;269;268	A,G;G,A;T	266,1;268,1;268	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5674	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3424	206.6	1	SNP	p	S87R	0	.	.	259	261	AGT	819	821	AGT	267;269;268	A,G;G,A;T	266,1;268,1;268	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5674	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3424	206.6	1	SNP	p	S87I	0	.	.	259	261	AGT	819	821	AGT	267;269;268	A,G;G,A;T	266,1;268,1;268	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5674	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3424	206.6	1	SNP	p	S88P	0	.	.	262	264	TCC	822	824	TCC	271;272;273	T;C;C	271;272;273	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5140	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3041	210.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1741	1743	GGC	281;279;281	G,A;G;C	280,1;279;281	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1584	1586	GCA	249;247;249	G;C;A	249;247;249	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1587	1589	ATC	249;249;247	A;T;C	249;249;247	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1599	1601	GTG	246;249;249	G;T;G	246;249;249	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1599	1601	GTG	246;249;249	G;T;G	246;249;249	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2103	2105	ACC	273;272;271	A;C;C	273;272;271	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2157	2159	GCG	268;265;266	G;C;G	268;265;266	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2157	2159	GCG	268;265;266	G;C;G	268;265;266	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2280	2282	GGC	237;235;237	G;G;C,T,G	237;235;235,1,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2289	2291	GGC	239;241;243	G;G;C	239;241;243	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4526	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	189.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2307	2309	CTG	245;246;247	C;T;G	245;246;247	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6312	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3693	213.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1918	1920	CCG	238;241;236	C,A;C;G	237,1;241;236	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2730	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2387	142.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	846	846	C	207	C	207	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	100	94.0	porB1a.l15.c17.ctg.2	180	57.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	131	133	ACG	72;72;71	A;C;G	72;72;71	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	100	94.0	porB1a.l15.c17.ctg.2	180	57.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	173	175	CAA	20;18;17	C;A;A	20;18;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	22;24;24	T;T;A	22;24;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	52;52;52	C;A;T	52;52;52	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	52;52;52	A;G;T	52;52;52	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	52;52;52	T;A;C	52;52;52	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	286	porB1a	984	226	90.27	porB1a.l15.c17.ctg.4	295	23.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	579	581	GAA	271;273;274	G;A;A	271;273;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	867	869	GAT	274;275;275	G;A;T	274;275;275	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	990	992	TCA	307;308;306	T;C,T,G;A	307;306,1,1;306	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1119	1121	GTC	242;243;248	G;T;C	242;243;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1449	1451	GCA	266;269;273	G;C,A;A	266;268,1;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	1	SNP	p	G120K	1	.	.	358	360	AAG	825	827	AAG	250;253;255	A;A;G	250;253;255	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	1	SNP	p	A121D	1	.	.	361	363	GAC	828	830	GAC	253;255;255	G;A;C	253;255;255	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3212	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1886	210.4	1	SNP	p	D121N	0	.	.	361	363	GAC	828	830	GAC	253;255;255	G;A;C	253;255;255	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11098	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5378	257.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2294	2296	AAT	292;290;293	A,G;A;T	291,1;290;293	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1568	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1522	128.2	1	SNP	p	V57M	1	.	.	169	171	ATG	788	790	ATG	293;293;293	A;T;G	293;293;293	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
